OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03 Material Modification to Rights of Security Holders.
On December 23, 2019, OWC Pharmaceutical Research Corp., filed with the Secretary of State of the State of Delaware a Certificate of Designation with respect to its Series B Convertible Preferred Stock (the “Certificate of Designation”). The Certificate of Designations designates 150,000 shares of its authorized but previously undesignated shares of preferred stock as Series B Convertible Preferred Stock, par value $0.00001 per share (the “Preferred Stock”). Each share of the Preferred Stock is convertible at the option of the holder or the Company into 1,000 shares of the Company’s Common Stock, par value $0.00001 per share (the “Common Stock”), provided that, at the time of conversion there are a sufficient number of shares of authorized but unissued shares of Common Stock that are not reserved for other purposes. With respect to the payment of dividends, redemption rights and distributions and payments upon liquidation, dissolution or winding up, the Preferred Stock will be equal in rank to the Common Stock and junior in rank to the Company’s Series A Convertible Preferred Stock and all shares of preferred capital stock of the Company that may be issued in the future, unless such preferred capital stock issued in the future is expressly junior in rank to the Preferred Stock.
In connection with the previously disclosed settlement between the Company and Ziv Turner, the former General Manager of the Company’s subsidiary, One World Cannabis Ltd, the Company will issue 43,675 Preferred Stock in satisfaction of the Company’s initial obligations under the settlement.
The foregoing summary of the Certificate of Designation is not complete and is qualified in its entirety by reference to the Certificate of Designation, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On December 23, 2019, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges, qualifications, restrictions and limitations of the Series B Convertible Preferred Stock. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing. A copy of the Certificate of Designation is included as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
(a) The Company’s Special Meeting of Stockholders was held on December 20, 2019 (the “Meeting”). Stockholders voted on the matters set forth below.
(b) (1) A quorum was present at the Meeting in person or by proxy and the holders of shares entitled to vote on the following matter were voted in connection with the authorization of the Company’s Board of Directors to effect a reverse stock split of the Company’s outstanding Common Stock, $0.00001 par value per share, at any ratio up to 1-for-700, at such time as the Company’s Board of Directors shall determine, in its sole discretion, before December 31, 2020 (“Proposal No. 1”).
The number of votes cast with respect to this matter was as follows:
| 3.1 | Certificate of Designation of Series B Convertible Preferred Stock of OWC Pharmaceutical Research Corp. |
OWC Pharmaceutical Research Corp. Exhibit
EX-3.1 2 ex3-1.htm CERTIFICATE OF DESIGNATIONS,…
To view the full exhibit click here
About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.
